ClinicalTrials.gg

TargetBeta

WRN

WRN RecQ like helicase · also RECQL2, RECQ3 · Exonucleases

6 programs in company-led studies act on WRN, from 6 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
WRN Inhibitor RO7589831ruleBayerphase 222 running–NCIt
WRN Inhibitor EIK1005ruleEikon Therapeuticsphase 211 running–NCIt
WRN Inhibitor GSK4418959ruleGlaxoSmithKlinephase 211 running–NCIt
WRN Inhibitor NDI-219216ruleNimbus Wadjetphase 211 running–NCIt
WRN Inhibitor AMG 436ruleAmgenphase 111 running–NCIt
WRN Inhibitor MOMA-341ruleMOMA Therapeuticsphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.